Revenue (Tables)

12 Months Ended

Dec. 31, 2024

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

The following table presents the approximate percentage of our net sales by market group:

	2024		2023		2022
Biologics	39	%	37	%	41	%
Generics	17	%	20	%	18	%
Pharma	25	%	24	%	24	%
Contract-Manufactured Products	19	%	19	%	17	%
	100	%	100	%	100	%

The following table presents the approximate percentage of our net sales by product category:

	2024		2023		2022
High-Value Product Components	45	%	50	%	55	%
High-Value Product Delivery Devices	14	%	10	%	5	%
Standard Packaging	22	%	21	%	23	%
Contract-Manufactured Products	19	%	19	%	17	%
	100	%	100	%	100	%

Due to the Company's reassessment of product categories, beginning in the second quarter of 2023, certain product types have been moved from High-Value Product Components to High-Value Product Delivery Devices. No adjustments were made to the product categorization prior to the second quarter of 2023.

The following table presents the approximate percentage of our net sales by geographic location:

	2024		2023		2022
Americas	45	%	45	%	48	%
Europe, Middle East, Africa	46	%	46	%	43	%
Asia Pacific	9	%	9	%	9	%
	100	%	100	%	100	%

Schedule of Change in Contract with Customer, Asset and Liability

The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:

	($ in millions)
Contract assets, December 31, 2023	$	21.5
Contract assets, December 31, 2024	23.3
Change in contract assets - increase (decrease)	$	1.8
Deferred income, December 31, 2023	$	(53.9)
Deferred income, December 31, 2024	(53.2)
Change in deferred income - decrease (increase)	$	0.7